These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16412820)

  • 1. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
    Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
    Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is homocysteine toxic in uremia?
    Perna AF; Luciano MG; Pulzella P; Satta E; Capasso R; Lombardi C; Ingrosso D; De Santo NG
    J Ren Nutr; 2008 Jan; 18(1):12-7. PubMed ID: 18089438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of hyperhomocysteinemia and their management by folic acid.
    Perna AF; De Santo NG; Ingrosso D
    Miner Electrolyte Metab; 1997; 23(3-6):174-8. PubMed ID: 9387111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homocysteine in uremia.
    Perna AF; Ingrosso D; Lombardi C; Cesare CM; Acantora F; Satta E; De Santo NG
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S123-6. PubMed ID: 12612968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
    Perna AF; Castaldo P; Ingrosso D; De Santo NG
    J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic consequences of hyperhomocysteinemia in uremia.
    Perna AF; Ingrosso D; Satta E; Romano M; Cimmino A; Galletti P; Zappia V; De Santo NG
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S85-90. PubMed ID: 11576929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit.
    Perna AF; Ingrosso D; Violetti E; Luciano MG; Sepe I; Lanza D; Capasso R; Ascione E; Raiola I; Lombardi C; Stenvinkel P; Massy Z; De Santo NG
    Semin Dial; 2009; 22(4):351-6. PubMed ID: 19708980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action.
    Perna AF; Acanfora F; Satta E; Lombardi C; Ingrosso D; De Santo NG
    Semin Nephrol; 2004 Sep; 24(5):426-30. PubMed ID: 15490404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies.
    Perna AF; Sepe I; Lanza D; Pollastro RM; De Santo NG; Ingrosso D
    J Ren Nutr; 2012 Jan; 22(1):191-4. PubMed ID: 22200441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperhomocysteinemia in chronic renal failure].
    Sydor A; Sułowicz W
    Przegl Lek; 1999; 56(7-8):520-4. PubMed ID: 10575921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperhomocysteinemia in chronic renal failure.].
    Satta E; Perna AF; Lombardi C; Acanfora F; Violetti E; Romano MM; Capasso R; Pisano M; Paduano F; De Santo NG
    G Ital Nefrol; 2006; 23(5):480-9. PubMed ID: 17123261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
    Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk factors and cardiovascular disease in uremic patients].
    Valdés F; Morales JM
    Nefrologia; 2002; 22 Suppl 4():1-6. PubMed ID: 12123136
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperhomocysteinemia and macromolecule modifications in uremic patients.
    Perna AF; Capasso R; Lombardi C; Acanfora F; Satta E; Ingrosso D
    Clin Chem Lab Med; 2005; 43(10):1032-8. PubMed ID: 16197294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism.
    Perna AF; Castaldo P; De Santo NG; di Carlo E; Cimmino A; Galletti P; Zappia V; Ingrosso D
    Kidney Int; 2001 Jun; 59(6):2299-308. PubMed ID: 11380834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging cardiovascular risk factors in end-stage renal disease.
    Yaqoob MM
    J Nephrol; 2002; 15(2):205-8. PubMed ID: 12018642
    [No Abstract]   [Full Text] [Related]  

  • 18. [Metabolic consequences of inflammation in kidney failure].
    Guebre-Egziabher F; Fouque D
    Nephrologie; 2003; 24(7):383-6. PubMed ID: 14650751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences.
    Perna AF; Ingrosso D; Satta E; Lombardi C; Galletti P; D'Aniello A; De Santo NG
    J Am Soc Nephrol; 2004 Oct; 15(10):2747-54. PubMed ID: 15466280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics of hyperhomocysteinemia in dialysis patients].
    Lovcić V; Kes P; Reiner Z
    Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.